CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 35 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04615572
NCT04615572N/ACompleted

Screening to Improve Survival in AL Amyloidosis

Tufts Medical Center·observational·Posted Nov 4, 2020·Updated Oct 28, 2024

In Brief

An observational study for Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance. Completed, enrolled 35 participants across 6 sites.

Detailed Summary

The purpose of this study is to see whether certain genes may be linked with the development of AL amyloidosis in subjects 60 years of age or older with the blood disorders SMM and MGUS. A limited repertoire of immunoglobulin (Ig) variable region genes have been associated with AL amyloidosis. The clonal plasma cells of subjects with SMM and MGUS may express one of these Ig variable region genes indicating a risk of progression to AL amyloidosis and potentially enabling early diagnosis. We hope this study will help us begin to understand whether Ig variable region gene identification can be a useful tool for assessing a subject's risk of progression to AL amyloidosis.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedNov 4, 2020
Enrollment StartAug 28, 2020
Primary CompletionJul 6, 2023
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 5.7 years ago